Erratum: Cancer treatment and survivor statistics (CA Cancer Journal for Clinicians (2012) DOI: 10.3322/caac.21149);Cancer treatment and survivorship statistics, 2012

CA Cancer Journal for Clinicians

Volumn 62, Issue 4, 2012, Pages 220-241

  Siegel, Rebecca ^a   Desantis, Carol ^a   Virgo, Katherine ^a   Stein, Kevin ^b   Mariotto, Angela ^c   Smith, Tenbroeck ^b   Cooper, Dexter ^b   Gansler, Ted ^a   Lerro, Catherine ^a   Fedewa, Stacey ^a   Lin, Chunchieh ^a   Leach, Corinne ^b   Cannady, Rachel Spillers ^b   Cho, Hyunsoon ^c   Scoppa, Steve ^d   Hachey, Mark ^d   Kirch, Rebecca ^a   Jemal, Ahmedin ^a   Ward, Elizabeth ^a  

^a AMERICAN CANCER SOCIETY   (United States)

^b BEHAVIORAL RESEARCH CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d INFORMATION MANAGEMENT SERVICES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; CHLORAMBUCIL; CISPLATIN; CRIZOTINIB; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIPODOPHYLLOTOXIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; HORMONE RECEPTOR; LEVOTHYROXINE; PANITUMUMAB; TAXANE DERIVATIVE; TENIPOSIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER PAIN; CANCER RADIOTHERAPY; CANCER STAGING; CANCER STATISTICS; CANCER SURVIVOR; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CAREGIVER; CHRONIC LYMPHATIC LEUKEMIA; COGNITIVE DEFECT; COLORECTAL CANCER; COLOSTOMY; DISTRESS SYNDROME; FATIGUE; FEMALE; GERM CELL TUMOR; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HEART ARRHYTHMIA; HEART DISEASE; HUMAN; HYSTERECTOMY; INFERTILITY; ISCHEMIA; LUNG DISEASE; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; LYMPHEDEMA; MAJOR CLINICAL STUDY; MALE; MASTECTOMY; MEDICARE; MELANOMA SKIN CANCER; NONHODGKIN LYMPHOMA; ORCHIECTOMY; PAIN; PHYSICAL ACTIVITY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RISK REDUCTION; SALPINGOOOPHORECTOMY; SEMINOMA; SEXUAL DYSFUNCTION; SMOKING CESSATION; SOCIAL PSYCHOLOGY; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TESTIS CANCER; THYROID CANCER; UNITED STATES; UTERUS CANCER; UTERUS CARCINOMA;

EID: 84863707351     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21154     Document Type: Erratum

References (188)

1. Mullan F,. Seasons of survival: reflections of a physician with cancer. N Engl J Med. 1985; 313: 270-273.
2. Verdecchia A, De Angelis G, Capocaccia R,. Estimation and projections of cancer prevalence from cancer registry data. Stat Med. 2002; 21: 3511-3526. (Pubitemid 35314665)
3. Mariotto AB, Yabroff KR, Feuer EJ, De Angelis R, Brown M,. Projecting the number of patients with colorectal carcinoma by phases of care in the US: 2000-2020. Cancer Causes Control. 2006; 17: 1215-1226. (Pubitemid 44772821)
4. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML,. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011; 103: 117-128.
5. Zhu L, Pickle LW, Ghosh K, et al. Predicting US- and state-level cancer counts for the current calendar year: Part II: evaluation of spatiotemporal projection methods for incidence. Cancer. 2012; 118: 1100-1109.
6. Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute, 2011.
7. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 17 Regs Public Use, Nov. 2010 Sub (2000-2008)-Linked to County Attributes-Total US, 1969-2008 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch; 2011.
8. Surveillance, Epidemiology, and End Results (SEER)Stat software. Version 7.0.5. Bethesda, MD: Statistical Research and Applications Branch, National Cancer Institute; 2011.
9. American College of Surgeons Commission on Cancer. National Cancer Data Base, 2008 Data Submission. Chicago, IL: American College of Surgeons; 2011.
10. Bilimoria KY, Bentrem DJ, Stewart AK, Winchester DP, Ko CY,. Comparison of commission on cancer-approved and -nonapproved hospitals in the United States: implications for studies that use the National Cancer Data Base. J Clin Oncol. 2009; 27: 4177-4181.
11. Fedewa SA, Etzioni R, Flanders WD, Jemal A, Ward EM,. Association of insurance and race/ethnicity with disease severity among men diagnosed with prostate cancer, National Cancer Database 2004-2006. Cancer Epidemiol Biomarkers Prev. 2010; 19: 2437-2444.
12. Bhargava A, Du XL,. Racial and socioeconomic disparities in adjuvant chemotherapy for older women with lymph node-positive, operable breast cancer. Cancer. 2009; 115: 2999-3008.
13. Fedewa SA, Ward EM, Stewart AK, Edge SB,. Delays in adjuvant chemotherapy treatment among patients with breast cancer are more likely in African American and Hispanic populations: a national cohort study 2004-2006. J Clin Oncol. 2010; 28: 4135-4141.
14. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG,. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993; 31: 732-748.
15. Surveillance, Epidemiology, and End Results Program. SEER-Medicare Data (2004-2006). Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Applied Research Program, Health Services and Economics Branch; 2010.
16. Jatoi I, Proschan MA,. Randomized trials of breast-conserving therapy versus mastectomy for primary breast cancer: a pooled analysis of updated results. Am J Clin Oncol. 2005; 28: 289-294. (Pubitemid 40800482)
17. Alderman AK, Hawley ST, Waljee J, Morrow M, Katz SJ,. Correlates of referral practices of general surgeons to plastic surgeons for mastectomy reconstruction. Cancer. 2007; 109: 1715-1720. (Pubitemid 46668531)
18. Alderman AK, Wei Y, Birkmeyer JD,. Use of breast reconstruction after mastectomy following the Women's Health and Cancer Rights Act. JAMA. 2006; 295: 387-388. (Pubitemid 43144974)
19. Christian CK, Niland J, Edge SB, et al. A multi-institutional analysis of the socioeconomic determinants of breast reconstruction: a study of the National Comprehensive Cancer Network. Ann Surg. 2006; 243: 241-249. (Pubitemid 43185444)
20. Lee CN, Belkora J, Chang Y, Moy B, Partridge A, Sepucha K,. Are patients making high-quality decisions about breast reconstruction after mastectomy? [outcomes article]. Plast Reconstr Surg. 2011; 127: 18-26.
21. Tseng JF, Kronowitz SJ, Sun CC, et al. The effect of ethnicity on immediate reconstruction rates after mastectomy for breast cancer. Cancer. 2004; 101: 1514-1523. (Pubitemid 39318896)
22. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005; 353: 1784-1792. (Pubitemid 41549890)
23. Petrek JA, Senie RT, Peters M, Rosen PP,. Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer. 2001; 92: 1368-1377. (Pubitemid 32947819)
24. Lawenda BD, Mondry TE, Johnstone PA,. Lymphedema: a primer on the identification and management of a chronic condition in oncologic treatment. CA Cancer J Clin. 2009; 59: 8-24.
25. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006; 355: 1572-1582. (Pubitemid 44547808)
26. Inskip PD, Curtis RE,. New malignancies following childhood cancer in the United States, 1973-2002. Int J Cancer. 2007; 121: 2233-2240. (Pubitemid 47585603)
27. Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003; 21: 774-780. (Pubitemid 46606434)
28. Hallbook H, Gustafsson G, Smedmyr B, Soderhall S, Heyman M,; Swedish Adult Acute Lymphocytic Leukemia Group; Swedish Childhood Leukemia Group. Treatment outcome in young adults and children > 10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol. Cancer. 2006; 107: 1551-1561. (Pubitemid 44546916)
29. Bleyer A,. Young adult oncology: the patients and their survival challenges. CA Cancer J Clin. 2007; 57: 242-255. (Pubitemid 47312083)
30. Bleyer A, O'Leary M, Barr R, Ries LAG,. Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival: 1975-2000. NIH Pub. No. 06-5767. Bethesda, MD: National Cancer Institute; 2006.
31. American Cancer Society. Cancer Prevention & Early Detection Facts & Figures 2012. Atlanta, GA: American Cancer Society; 2012.
32. Jansen L, Koch L, Brenner H, Arndt V,. Quality of life among long-term (≥ 5 years) colorectal cancer survivors-systematic review. Eur J Cancer. 2010; 46: 2879-2888.
33. Curtis RE, Freedman DM, Ron E, et al. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. NIH Pub. No. 05-5302, Bethesda, MD: National Cancer Institute; 2006.
34. Institute of Medicine. From Cancer Patient to Cancer Survivor: Lost in Transition. Washington, DC: The National Academies Press; 2006.
35. Linet MS, Devesa SS, Morgan GJ,. The leukemias. In:, Schottenfeld D, Fraumeni JF, eds. Cancer Epidemiology and Prevention. New York: Oxford University Press, Inc; 2006: 841-871.
36. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009; 360: 2730-2741.
37. Veerman AJ, Kamps WA, van den Berg H, et al. Dutch Childhood Oncology Group. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol. 2009; 10: 957-966.
38. Pui CH, Behm FG, Raimondi SC, et al. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med. 1989; 321: 136-142. (Pubitemid 19180676)
39. Tsai HK, Mauch PM,. Nodular lymphocyte-predominant hodgkin lymphoma. Semin Radiat Oncol. 2007; 17: 184-189. (Pubitemid 46963029)
40. Lossos IS, Alizadeh AA, Diehn M, et al. Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci U S A. 2002; 99: 8886-8891. (Pubitemid 34693653)
41. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365: 395-409.
42. Chapple A, Ziebland S, McPherson A,. Stigma, shame, and blame experienced by patients with lung cancer: qualitative study. BMJ. 2004; 328: 1470-1476.
43. Freedman DM, Miller BA, Tucker MA,. New malignancies following melanoma of the skin, eye melanoma, and non-melanoma eye cancer. In:, Curtis RE, Freedman DM, Ron E, et al, eds. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. NIH Pub. No. 05-5302. Bethesda, MD: National Cancer Institute; 2006: 339-362.
44. Albertsen PC, Hanley JA, Fine J,. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005; 293: 2095-2101. (Pubitemid 40617061)
45. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA. 2009; 302: 1202-1209.
46. Shappley WV,3rd, Kenfield SA, Kasperzyk JL, et al. Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol. 2009; 27: 4980-4985.
47. Kintzel PE, Chase SL, Schultz LM, O'Rourke TJ,. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy. 2008; 28: 1511-1522.
48. Townsend JS, Richardson LC, German RR,. Incidence of testicular cancer in the United States, 1999-2004. Am J Mens Health. 2010; 4: 353-360.
49. Davies L, Ouellette M, Hunter M, Welch HG,. The increasing incidence of small thyroid cancers: where are the cases coming from? Laryngoscope. 2010; 120: 2446-2451.
50. Davies L, Welch HG,. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006; 295: 2164-2167.
51. Aschebrook-Kilfoy B, Ward MH, Sabra MM, Devesa SS,. Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006. Thyroid. 2011; 21: 125-134.
52. Chen Z, Maricic M, Bassford TL, et al. Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. Arch Intern Med. 2005; 165: 552-558. (Pubitemid 40344388)
53. Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev. 2009; 18: 784-791.
54. Haymart MR, Banerjee M, Stewart AK, Koenig RJ, Birkmeyer JD, Griggs JJ,. Use of radioactive iodine for thyroid cancer. JAMA. 2011; 306: 721-728.
55. Efstathiou JA, Spiegel DY, Shipley WU, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol. 2012; 61: 705-711.
56. Heney NM, Ahmed S, Flanagan MJ, et al. Superficial bladder cancer: progression and recurrence. J Urol. 1983; 130: 1083-1086. (Pubitemid 14207227)
57. Lutzeyer W, Rubben H, Dahm H,. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol. 1982; 127: 250-252. (Pubitemid 12131747)
58. Gore JL, Saigal CS, Hanley JM, Schonlau M, Litwin MS,; Urologic Diseases in America Project. Variations in reconstruction after radical cystectomy. Cancer. 2006; 107: 729-737. (Pubitemid 44232665)
59. Gilbert SM, Wood DP, Dunn RL, et al. Measuring health-related quality of life outcomes in bladder cancer patients using the Bladder Cancer Index (BCI). Cancer. 2007; 109: 1756-1762. (Pubitemid 46668537)
60. Barbera L, Seow H, Howell D, et al. Symptom burden and performance status in a population-based cohort of ambulatory cancer patients. Cancer. 2010; 116: 5767-5776.
61. Patrick DL, Ferketich SL, Frame PS, et al. National Institutes of Health State-of-the-Science Panel. National Institutes of Health State-of-the-Science Conference Statement: symptom management in cancer: pain, depression, and fatigue, July 15-17, 2002. J Natl Cancer Inst Monogr. 2004 (32): 9-16.
62. Gralow JR, Biermann JS, Farooki A, et al. NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw. 2009; 7 (suppl 3): S1-S32; quiz S33-S35.
63. Pfeilschifter J, Diel IJ,. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol. 2000; 18: 1570-1593. (Pubitemid 30205404)
64. Tipples K, Robinson A,. Optimal management of cancer treatment-induced bone loss: considerations for elderly patients. Drugs Aging. 2011; 28: 867-883.
65. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT,. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol. 2000; 163: 181-186.
66. Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM,. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab. 2002; 87: 3656-3661. (Pubitemid 34879508)
67. Smith MR,. Osteoporosis during androgen deprivation therapy for prostate cancer. Urology. 2002; 60 (3 suppl 1): 79-85; discussion 86.
68. Smith MR,. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. Cancer. 2003; 97 (suppl 3): 789-795. (Pubitemid 36125814)
69. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS,. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005; 352: 154-164. (Pubitemid 40096612)
70. Ewer MS, Ewer SM,. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol. 2010; 7: 564-575.
71. Steinherz LJ, Yahalom J,. Cardiac toxicity. In:, DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001: 2904-2931.
72. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML,. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991; 266: 1672-1677.
73. Fuchs IB, Landt S, Bueler H, et al. Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin). Breast Cancer Res Treat. 2003; 82: 23-28. (Pubitemid 37476016)
74. Klein PM, Dybdal N,. Trastuzumab and cardiac dysfunction: update on preclinical studies. Semin Oncol. 2003; 30 (5 suppl 16): 49-53. (Pubitemid 37433396)
75. Perez EA, Rodeheffer R,. Clinical cardiac tolerability of trastuzumab. J Clin Oncol. 2004; 22: 322-329. (Pubitemid 41095098)
76. Eriksson F, Gagliardi G, Liedberg A, et al. Long-term cardiac mortality following radiation therapy for Hodgkin's disease: analysis with the relative seriality model. Radiother Oncol. 2000; 55: 153-162. (Pubitemid 30229990)
77. Harpham WS,. Long-term survivorship late effects. In:, Berger A, ed. Principles and Practice of Supportive Oncology. Philadelphia, PA: Lippincott-Raven; 1998: 889-907.
78. Stewart JR, Fajardo LF, Gillette SM, Constine LS,. Radiation injury to the heart. Int J Radiat Oncol Biol Phys. 1995; 31: 1205-1211.
79. Tukenova M, Guibout C, Oberlin O, et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol. 2010; 28: 1308-1315.
80. Ahles TA, Saykin A,. Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Invest. 2001; 19: 812-820. (Pubitemid 33151212)
81. Ahles TA, Saykin AJ, Furstenberg CT, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002; 20: 485-493. (Pubitemid 34072533)
82. Ahles TA,. Do systemic cancer treatments affect cognitive function? Lancet Oncol. 2004; 5: 270-271. (Pubitemid 38541577)
83. Burstein HJ,. Cognitive side-effects of adjuvant treatments. Breast. 2007; 16 (suppl 2): S166-S168.
84. Schultz PN, Beck ML, Stava C, Vassilopoulou-Sellin R,. Health profiles in 5836 long-term cancer survivors. Int J Cancer. 2003; 104: 488-495. (Pubitemid 36323921)
85. Tannock IF, Ahles TA, Ganz PA, van Dam FS,. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol. 2004; 22: 2233-2239. (Pubitemid 41095159)
86. Tchen N, Juffs HG, Downie FP, et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol. 2003; 21: 4175-4183. (Pubitemid 46606186)
87. Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA,. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 2004; 100: 2292-2299. (Pubitemid 38657875)
88. Padovan CS, Yousry TA, Schleuning M, Holler E, Kolb HJ, Straube A,. Neurological and neuroradiological findings in long-term survivors of allogeneic bone marrow transplantation. Ann Neurol. 1998; 43: 627-633. (Pubitemid 28225554)
89. Ganz PA,. "Doctor, will the treatment you are recommending cause chemobrain?". J Clin Oncol. 2012; 30: 229-231.
90. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Distress Management. Version 1.2012. Fort Washington, PA: National Comprehensive Cancer Network; 2012.
91. Mitchell AJ, Chan M, Bhatti H, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011; 12: 160-174.
92. Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR,. Cancer-related fatigue: the scale of the problem. Oncologist. 2007; 12 (suppl 1): 4-10.
93. Berger AM, Abernethy AP, Atkinson A, et al. Cancer-related fatigue. J Natl Compr Canc Netw. 2010; 8: 904-931.
94. Cella DF, Lai JS, Chang CH, Peterman A, Slavin M,. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 2002; 94: 528-538. (Pubitemid 34081385)
95. Dimeo FC,. Effects of exercise on cancer-related fatigue. Cancer. 2001; 92 (suppl 6): 1689-1693. (Pubitemid 32939176)
96. Stasi R, Abriani L, Beccaglia P, Terzoli E, Amadori S,. Cancer-related fatigue: evolving concepts in evaluation and treatment. Cancer. 2003; 98: 1786-1801. (Pubitemid 37310220)
97. Fossa SD, Dahl AA, Loge JH,. Fatigue, anxiety, and depression in long-term survivors of testicular cancer. J Clin Oncol. 2003; 21: 1249-1254. (Pubitemid 46606400)
98. Hwang SS, Chang VT, Rue M, Kasimis B,. Multidimensional independent predictors of cancer-related fatigue. J Pain Symptom Manage. 2003; 26: 604-614. (Pubitemid 36802284)
99. Bower JE, Ganz PA, Aziz N, Fahey JL,. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med. 2002; 64: 604-611. (Pubitemid 34791163)
100. Bower JE, Ganz PA, Aziz N, Fahey JL, Cole SW,. T-cell homeostasis in breast cancer survivors with persistent fatigue. J Natl Cancer Inst. 2003; 95: 1165-1168. (Pubitemid 37045395)
101. Knobel H, Loge JH, Nordoy T, et al. High level of fatigue in lymphoma patients treated with high dose therapy. J Pain Symptom Manage. 2000; 19: 446-456. (Pubitemid 30447370)
102. Minton O, Stone P,. How common is fatigue in disease-free breast cancer survivors? A systematic review of the literature. Breast Cancer Res Treat. 2008; 112: 5-13.
103. Andrykowski MA, Schmidt JE, Salsman JM, Beacham AO, Jacobsen PB,. Use of a case definition approach to identify cancer-related fatigue in women undergoing adjuvant therapy for breast cancer. J Clin Oncol. 2005; 23: 6613-6622. (Pubitemid 46190255)
104. Sadler IJ, Jacobsen PB, Booth-Jones M, Belanger H, Weitzner MA, Fields KK,. Preliminary evaluation of a clinical syndrome approach to assessing cancer-related fatigue. J Pain Symptom Manage. 2002; 23: 406-416. (Pubitemid 34463009)
105. Ruffer JU, Flechtner H, Tralls P, et al. German Hodgkin Lymphoma Study Group. Fatigue in long-term survivors of Hodgkin's lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG). Eur J Cancer. 2003; 39: 2179-2186. (Pubitemid 37297743)
106. Broeckel JA, Jacobsen PB, Horton J, Balducci L, Lyman GH,. Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol. 1998; 16: 1689-1696. (Pubitemid 28234711)
107. Jacobsen PB, Stein K,. Is fatigue a long-term side effect of breast cancer treatment? Cancer Control. 1999; 6: 256-263. (Pubitemid 29237340)
108. Servaes P, van der Werf S, Prins J, Verhagen S, Bleijenberg G,. Fatigue in disease-free cancer patients compared with fatigue in patients with chronic fatigue syndrome. Support Care Cancer. 2001; 9: 11-17. (Pubitemid 32125584)
109. Holzner B, Kemmler G, Meraner V, et al. Fatigue in ovarian carcinoma patients: a neglected issue? Cancer. 2003; 97: 1564-1572. (Pubitemid 36297787)
110. Hann DM, Jacobsen PB, Martin SC, Kornish LE, Azzarello LM, Fields KK,. Fatigue in women treated with bone marrow transplantation for breast cancer: a comparison with women with no history of cancer. Support Care Cancer. 1997; 5: 44-52. (Pubitemid 27163467)
111. Brown JC, Huedo-Medina TB, Pescatello LS, et al. Efficacy of exercise interventions in modulating cancer-related fatigue among adult cancer survivors: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2011; 20: 123-133.
112. Jacobsen PB, Donovan KA, Vadaparampil ST, et al. Systematic review and meta-analysis of psychological and activity-based interventions for cancer-related fatigue. Health Psychol. 2007; 26: 660-667. (Pubitemid 350161067)
113. Minton O, Richardson A, Sharpe M, et al. Psychostimulants for the management of cancer-related fatigue: a systematic review and meta-analysis. J Pain Symptom Manage. 2011; 41: 761-767.
114. Humphris GM, Rogers S, McNally D, Lee-Jones C, Brown J, Vaughan D,. Fear of recurrence and possible cases of anxiety and depression in orofacial cancer patients. Int J Oral Maxillofac Surg. 2003; 32: 486-491. (Pubitemid 38263347)
115. Lee-Jones C, Humphris G, Dixon R, Hatcher MB,. Fear of cancer recurrence-a literature review and proposed cognitive formulation to explain exacerbation of recurrence fears. Psychooncology. 1997; 6: 95-105. (Pubitemid 27288402)
116. Mehta SS, Lubeck DP, Pasta DJ, Litwin MS,. Fear of cancer recurrence in patients undergoing definitive treatment for prostate cancer: results from CaPSURE. J Urol. 2003; 170: 1931-1933. (Pubitemid 37254963)
117. Northouse LL,. Mastectomy patients and the fear of cancer recurrence. Cancer Nurs. 1981; 4: 213-220.
118. Vickberg SM,. The Concerns About Recurrence Scale (CARS): a systematic measure of women's fears about the possibility of breast cancer recurrence. Ann Behav Med. 2003; 25: 16-24. (Pubitemid 36182455)
119. Baker F, Denniston M, Smith T, West MM,. Adult cancer survivors: how are they faring? Cancer. 2005; 104 (suppl 11): 2565-2576. (Pubitemid 41691539)
120. Mellon S, Kershaw TS, Northouse LL, Freeman-Gibb L,. A family-based model to predict fear of recurrence for cancer survivors and their caregivers. Psychooncology. 2007; 16: 214-223. (Pubitemid 46380545)
121. Jeruss JS, Woodruff TK,. Preservation of fertility in patients with cancer. N Engl J Med. 2009; 360: 902-911.
122. Knobf MT,. The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors. Oncologist. 2006; 11: 96-110. (Pubitemid 43261757)
123. Hudson MM,. Reproductive outcomes for survivors of childhood cancer. Obstet Gynecol. 2010; 116: 1171-1183.
124. Huddart RA, Norman A, Moynihan C, et al. Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer. 2005; 93: 200-207. (Pubitemid 41133206)
125. Nieman CL, Kazer R, Brannigan RE, et al. Cancer survivors and infertility: a review of a new problem and novel answers. J Support Oncol. 2006; 4: 171-178. (Pubitemid 43890976)
126. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J,. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007; 18: 1437-1449. (Pubitemid 47365475)
127. Green CR, Hart-Johnson T, Loeffler DR,. Cancer-related chronic pain: examining quality of life in diverse cancer survivors. Cancer. 2011; 117: 1994-2003.
128. Argyriou AA, Koltzenburg M, Polychronopoulos P, Papapetropoulos S, Kalofonos HP,. Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol. 2008; 66: 218-228.
129. World Health Organization. Cancer Pain Relief: With a Guide to Opioid Availability, 2nd ed. Geneva, Switzerland: World Health Organization; 1996.
130. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Adult Cancer Pain. Version 2.2011. Fort Washington, PA: National Comprehensive Cancer Network; 2011.
131. Liles A, Blatt J, Morris D, et al. Children's Oncology Group. Monitoring pulmonary complications in long-term childhood cancer survivors: guidelines for the primary care physician. Cleve Clin J Med. 2008; 75: 531-539.
132. Mertens AC, Yasui Y, Liu Y, et al. Childhood Cancer Survivor Study. Pulmonary complications in survivors of childhood and adolescent cancer. A report from the Childhood Cancer Survivor Study. Cancer. 2002; 95: 2431-2441. (Pubitemid 35351152)
133. Jenkins R, Schover LR, Fouladi RT, et al. Sexuality and health-related quality of life after prostate cancer in African-American and white men treated for localized disease. J Sex Marital Ther. 2004; 30: 79-93. (Pubitemid 38228857)
134. Neese LE, Schover LR, Klein EA, Zippe C, Kupelian PA,. Finding help for sexual problems after prostate cancer treatment: a phone survey of men's and women's perspectives. Psychooncology. 2003; 12: 463-473. (Pubitemid 36873982)
135. Frumovitz M, Sun CC, Schover LR, et al. Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol. 2005; 23: 7428-7436. (Pubitemid 46291804)
136. Ganz PA, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE,. Life after breast cancer: understanding women's health-related quality of life and sexual functioning. J Clin Oncol. 1998; 16: 501-514. (Pubitemid 28135592)
137. Kornblith AB, Ligibel J,. Psychosocial and sexual functioning of survivors of breast cancer. Semin Oncol. 2003; 30: 799-813. (Pubitemid 38010133)
138. Siegel T, Moul JW, Spevak M, Alvord WG, Costabile RA,. The development of erectile dysfunction in men treated for prostate cancer. J Urol. 2001; 165: 430-435. (Pubitemid 32060430)
139. Schover LR,. Sexuality and fertility after cancer. Hematology Am Soc Hematol Educ Program. 2005: 523-527.
140. Meier DE, Brawley OW,. Palliative care and the quality of life. J Clin Oncol. 2011; 29: 2750-2752.
141. Morrison RS, Meier DE,. America's Care of Serious Illness: A State-by-State Report Card on Access to Palliative Care in Our Nation's Hospitals. New York, NY: Center to Advance Palliative Care; 2011.
142. Hui D, Elsayem A, De la Cruz M, et al. Availability and integration of palliative care at US cancer centers. JAMA. 2010; 303: 1054-1061.
143. Fashoyin-Aje LA, Martinez KA, Dy SM,. New patient-centered care standards from the Commission on Cancer: opportunities and challenges [published online ahead of print March 20, 2012]. J Support Oncol.
144. Jacobs LA, Palmer SC, Schwartz LA, et al. Adult cancer survivorship: evolution, research, and planning care. CA Cancer J Clin. 2009; 59: 391-410.
145. Salz T, Oeffinger KC, McCabe MS, Layne TM, Bach PB,. Survivorship care plans in research and practice [published online ahead of print January 12, 2012]. CA Cancer J Clin. doi: 10.3322/caac.20142.
146. Hede K,. Assessing survivorship care plans. J Natl Cancer Inst. 2011; 103: 1214-1215.
147. Ferrell BR, Hassey Dow K,. Quality of life among long-term cancer survivors. Oncology (Williston Park). 1997; 11: 565-568, 571; discussion 572, 575-576.
148. Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz BE, Belin TR,. Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst. 2002; 94: 39-49. (Pubitemid 34082842)
149. Ashing-Giwa KT, Tejero JS, Kim J, Padilla GV, Hellemann G,. Examining predictive models of HRQOL in a population-based, multiethnic sample of women with breast carcinoma. Qual Life Res. 2007; 16: 413-428. (Pubitemid 46363698)
150. Mols F, Vingerhoets AJ, Coebergh JW, van de Poll-Franse LV,. Quality of life among long-term breast cancer survivors: a systematic review. Eur J Cancer. 2005; 41: 2613-2619. (Pubitemid 41613712)
151. Zeltzer LK, Lu Q, Leisenring W, et al. Psychosocial outcomes and health-related quality of life in adult childhood cancer survivors: a report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev. 2008; 17: 435-446. (Pubitemid 351272798)
152. Bowen DJ, Alfano CM, McGregor BA, et al. Possible socioeconomic and ethnic disparities in quality of life in a cohort of breast cancer survivors. Breast Cancer Res Treat. 2007; 106: 85-95. (Pubitemid 47498096)
153. Hewitt M, Rowland JH, Yancik R,. Cancer survivors in the United States: age, health, and disability. J Gerontol A Biol Sci Med Sci. 2003; 58: 82-91. (Pubitemid 36110060)
154. Sweeney C, Schmitz KH, Lazovich D, Virnig BA, Wallace RB, Folsom AR,. Functional limitations in elderly female cancer survivors. J Natl Cancer Inst. 2006; 98: 521-529. (Pubitemid 43898815)
155. Zebrack BJ, Chesler MA,. Quality of life in childhood cancer survivors. Psychooncology. 2002; 11: 132-141. (Pubitemid 34256424)
156. Bower JE, Meyerowitz BE, Desmond KA, Bernaards CA, Rowland JH, Ganz PA,. Perceptions of positive meaning and vulnerability following breast cancer: predictors and outcomes among long-term breast cancer survivors. Ann Behav Med. 2005; 29: 236-245. (Pubitemid 40911142)
157. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ,. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003; 348: 1625-1638. (Pubitemid 36459468)
158. McTiernan A, Irwin M, Vongruenigen V,. Weight, physical activity, diet, and prognosis in breast and gynecologic cancers. J Clin Oncol. 2010; 28: 4074-4080.
159. Wei EK, Wolin KY, Colditz GA,. Time course of risk factors in cancer etiology and progression. J Clin Oncol. 2010; 28: 4052-4057.
160. Winzer BM, Whiteman DC, Reeves MM, Paratz JD,. Physical activity and cancer prevention: a systematic review of clinical trials. Cancer Causes Control. 2011; 22: 811-826.
161. Do KA, Johnson MM, Lee JJ, et al. Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies. Cancer. 2004; 101: 2837-2842. (Pubitemid 39603192)
162. Parsons A, Daley A, Begh R, Aveyard P,. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ. 2010; 340: b5569.
163. Blanchard CM, Stein KD, Baker F, et al. Association between current lifestyle behaviors and health-related quality of life in breast, colorectal, and prostate cancer survivors. Psychol Health. 2004; 19: 1-13. (Pubitemid 38170034)
164. Courneya KS, Mackey JR, Bell GJ, Jones LW, Field CJ, Fairey AS,. Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes. J Clin Oncol. 2003; 21: 1660-1668. (Pubitemid 46638575)
165. Mustian KM, Morrow GR, Carroll JK, Figueroa-Moseley CD, Jean-Pierre P, Williams GC,. Integrative nonpharmacologic behavioral interventions for the management of cancer-related fatigue. Oncologist. 2007; 12 (suppl 1): 52-67.
166. Kushi LH, Doyle C, McCullough M, et al. American Cancer Society, 2010 Nutrition and Physical Activity Guidelines Advisory Committee. American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. 2012; 62: 30-67.
167. Courneya KS,. Physical activity in cancer survivors: a field in motion. Psychooncology. 2009; 18: 337-342.
168. Irwin ML, Mayne ST,. Impact of nutrition and exercise on cancer survival. Cancer J. 2008; 14: 435-441.
169. Denlinger CS, Engstrom PF,. Colorectal cancer survivorship: movement matters. Cancer Prev Res (Phila). 2011; 4: 502-511.
170. Toles M, Demark-Wahnefried W,. Nutrition and the cancer survivor: evidence to guide oncology nursing practice. Semin Oncol Nurs. 2008; 24: 171-179.
171. Kushi LH, Byers T, Doyle C, et al. American Cancer Society 2006 Nutrition and Physical Activity Guidelines Advisory Committee. American Cancer Society Guidelines on Nutrition and Physical Activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. 2006; 56: 254-281; quiz 313-314. (Pubitemid 44527489)
172. Barrera S, Demark-Wahnefried W,. Nutrition during and after cancer therapy. Oncology (Williston Park). 2009; 23 (2 suppl Nurse Ed): 15-21.
173. Burke L, Miller LA, Saad A, Abraham J,. Smoking behaviors among cancer survivors: an observational clinical study. J Oncol Pract. 2009; 5: 6-9.
174. National Center for Health Statistics. National Health Interview Survey, 2000, 2005, and 2008. Hyattsville, MD: National Center for Health Statistics, Centers for Disease Control and Prevention; 2009.
175. Sanderson Cox L, Patten CA, Ebbert JO, et al. Tobacco use outcomes among patients with lung cancer treated for nicotine dependence. J Clin Oncol. 2002; 20: 3461-3469.
176. Yabroff KR, Kim Y,. Time costs associated with informal caregiving for cancer survivors. Cancer. 2009; 115 (suppl 18): 4362-4373.
177. van Ryn M, Sanders S, Kahn K, et al. Objective burden, resources, and other stressors among informal cancer caregivers: a hidden quality issue? Psychooncology. 2011; 20: 44-52.
178. Northouse LL, Katapodi MC, Song L, Zhang L, Mood DW,. Interventions with family caregivers of cancer patients: meta-analysis of randomized trials. CA Cancer J Clin. 2010; 60: 317-339.
179. Ganz PA,. A teachable moment for oncologists: cancer survivors, 10 million strong and growing! J Clin Oncol. 2005; 23: 5458-5460.
180. Humpel N, Magee C, Jones SC,. The impact of a cancer diagnosis on the health behaviors of cancer survivors and their family and friends. Support Care Cancer. 2007; 15: 621-630. (Pubitemid 47034991)
181. Kim Y, Carver CS, Spillers RL, Love-Ghaffari M, Kaw CK,. Dyadic effects of fear of recurrence on the quality of life of cancer survivors and their caregivers. Qual Life Res. 2012; 21: 517-525.
182. Given BA, Sherwood P, Given CW,. Support for caregivers of cancer patients: transition after active treatment. Cancer Epidemiol Biomarkers Prev. 2011; 20: 2015-2021.
183. Northouse LL, Mood D, Templin T, Mellon S, George T,. Couples' patterns of adjustment to colon cancer. Soc Sci Med. 2000; 50: 271-284. (Pubitemid 29465764)
184. Hagedoorn M, Buunk BP, Kuijer RG, Wobbes T, Sanderman R,. Couples dealing with cancer: role and gender differences regarding psychological distress and quality of life. Psychooncology. 2000; 9: 232-242. (Pubitemid 30392198)
185. Kim Y, Loscalzo MJ, Wellisch DK, Spillers RL,. Gender differences in caregiving stress among caregivers of cancer survivors. Psychooncology. 2006; 15: 1086-1092. (Pubitemid 46040596)
186. Matthews B, Baker F, Spillers R,. Family caregivers and indicators of cancer-related distress. Psychol Health Med. 2003; 8: 46-56.
187. Kim Y, Schulz R, Carver CS,. Benefit-finding in the cancer caregiving experience. Psychosom Med. 2007; 69: 283-291.
188. Carver CS, Antoni MH,. Finding benefit in breast cancer during the year after diagnosis predicts better adjustment 5 to 8 years after diagnosis. Health Psychol. 2004; 23: 595-598. (Pubitemid 39447329)